These cellular events underscore the findings of our current study, suggesting that autophagy inhibition can strategically increase NO bioavailability by sustaining GCH1 homeostasis, providing a potentially valuable therapeutic strategy to counteract the endothelial dysfunction characteristic of PAH and other vascular diseases where NO production is compromised. Here, GCH1 is linked to pulmonary arterial hypertension.